• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Device for treating challenging bone fractures cleared by FDA

Bioengineer by Bioengineer
July 20, 2023
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A new system for fixing bone fractures, called the Bone Bolt System, has been approved for market by the U.S. Food and Drug Administration (FDA), the University of Utah Orthopaedic Innovation Center (OIC), Department of Orthopaedics and Spencer Fox Eccles School of Medicine announced on July 20, 2023.

Repair with Bone Bolt System

Credit: Wade Fallin

A new system for fixing bone fractures, called the Bone Bolt System, has been approved for market by the U.S. Food and Drug Administration (FDA), the University of Utah Orthopaedic Innovation Center (OIC), Department of Orthopaedics and Spencer Fox Eccles School of Medicine announced on July 20, 2023.

“This achievement demonstrates the commitment by the Department of Orthopaedics to bring new and innovative solutions to advance the quality of orthopaedic patient care,” said Darrel S. Brodke, M.D., Jack and Hazel Robertson Presidential Professor and chair of the Department of Orthopaedics. “It is the dynamic collaboration between our clinical faculty, trainees, our discovery research group and our innovation research group, known as the OIC, that led to this advancement, a first of many to come.”  

The FDA granted the Bone Bolt System a 510(k) clearance to sell and market the device in the U.S. This milestone marks the first time that a novel medical device has received an FDA 510(k) clearance in University of Utah’s history.

“As one of the nation’s leading research universities, innovation plays a central role in our mission to improve the quality of life of our patients—OIC’s Bone Bolt System does just that,” said University of Utah President Taylor Randall. “Not only will the device make a difference in the care we can provide at University of Utah Health, but it illustrates our commitment to turn research into real-world impact by getting it to market as soon as possible, to improve health outcomes more broadly.”

The Bone Bolt System is a novel implant system designed and developed by the OIC for percutaneous bone fracture fixation. The system is a comprehensive set of implants of various lengths and diameters, along with associated surgical instruments and sterilization trays. The implants are used to treat challenging bone fractures, such as pelvic fractures and fractures of the long bones in the arm and leg. The Bone Bolt System is protected by U.S. Patent No. 11,553,948, with other U.S. and international patents pending.

The OIC submitted a 510(k) to the FDA to demonstrate that the medical device is safe and effective, or “substantially equivalent,” to an existing FDA 510(k) cleared device. Upon 510(k) clearance by the FDA, the medical device may be legally marketed in the U.S. 

The OIC has developed the Bone Bolt System in full compliance with the FDA Quality System Regulations and ISO 13485 Medical Devices—Quality Management Systems. Additionally, the OIC has developed a commercial supply chain for the Bone Bolt System. The next step, to be led by the OIC and the University of Utah PIVOT Center, will be establishing industry partnerships to commercialize the Bone Bolt System and bring it to hospitals and surgery centers throughout the country for the benefit of orthopaedic patients. 

“The simplicity of the Bone Bolt procedure to effectively stabilize complex fractures will impact the standard of care for patients with challenging fractures. The thoughtfulness during development of the Bone Bolt System encourages rapid adoption as the development team considered the care provider’s perspective in conjunction with clinical outcomes,” said PIVOT Associate Director of Innovation & Commercialization Huy Tran. “PIVOT Center is looking forward to engaging with potential industry partners to commercialize the technology and make an immediate impact on the quality of life for patients.”

About the Orthopaedic Innovation Center (“OIC”)

The OIC, opened in January 2021, is a collaborative effort between the Department of Orthopaedics and the University of Utah’s PIVOT Center to design, develop and commercialize novel implants and instruments that will improve the care of patients with musculoskeletal disorders. For more information regarding the OIC, contact Wade Fallin at [email protected].

About University of Utah Health

University of Utah Health  provides leading-edge and compassionate care for a referral area that encompasses Idaho, Wyoming, Montana and much of Nevada. A hub for health sciences research and education in the region, U of U Health has a $458 million research enterprise and trains the majority of Utah’s physicians, and more than 1,670 scientists and 1,460 health care providers at its Colleges of Health, Nursing and Pharmacy and Schools of Dentistry and Medicine. With more than 20,000 employees, the system includes 12 community clinics and five hospitals. U of U Health is recognized nationally as a transformative health care system and provider of world-class care.



Share12Tweet8Share2ShareShareShare2

Related Posts

Inside CNS Solitary Fibrous Tumors: Genetics and Therapies

Inside CNS Solitary Fibrous Tumors: Genetics and Therapies

August 23, 2025
Brain-Delivered Antibody Targets Alpha-Synuclein Aggregates

Brain-Delivered Antibody Targets Alpha-Synuclein Aggregates

August 23, 2025

Multi-Omics Reveal Nerve Macrophages in Polyneuropathy

August 23, 2025

Optimizing Basal Insulin Titration: Digital Solutions in India

August 23, 2025

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Impact of Moderate Warming on Soil Microbial Decomposition

Inside CNS Solitary Fibrous Tumors: Genetics and Therapies

Brain-Delivered Antibody Targets Alpha-Synuclein Aggregates

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.